TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01106365

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: H-coil (Repetitive deep transcranial magnetic stimulation)
Description: Repetitive deep transcranial magnetic stimulation of prefrontal cortex or motor cortex or sham stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H-coil (Repetitive deep transcranial magnetic stimulation)
Description: Repetitive deep transcranial magnetic stimulation of prefrontal cortex or motor cortex or sham stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: H-coil (Repetitive deep transcranial magnetic stimulation)
Description: Repetitive deep transcranial magnetic stimulation of prefrontal cortex or motor cortex or sham stimulation
Study: NCT04519593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy with prior temporary uterine blood supply occlusion
Description: Visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic myomectomy
Description: Laparoscopic myomectomy without prior temporary uterine blood supply occlusion
Study: NCT01350232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Subjects will receive fludarabine at a dose of 30 mg/m2 daily for 4 days as part of the preparative regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Subjects will receive cytarabine at a dose of 2 g/m2 daily for 4 days, approximately 4 hours after the fludarabine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellular Infusions
Description: Subjects will receive the cellular product in 2 steps. The first is a lymphocyte infusion of 2 X 10e8 lymphocytes/kg on the day they receive total body irradiation. The second is a CD34 enriched stem cell product approximately 48 hours after the cyclophosphamide.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: All subjects will receive 200cGy TBI in a single fraction on the AM they receive the lymphocyte infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: All subjects will receive cyclophosphamide at a dose of 60 mg/kg at approximately 72 and 96 hours after the lymphocyte infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subjects will receive bortezomib 1.3 mg/kg on Day 1,4,8, and 11 of a 21 day cycle. This will be repeated for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Subjects will receive rituximab 375 mg/m2 on day 1 and day 8 of a 21 day cycle, on days they will also be receiving rituximab. This will be repeated for 2 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Subjects who continue to have detectable anti-donor antibody will receive plasmapheresis to reduce the antibody further
Study: NCT03189147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biceps Tenodesis
Description: Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement
Description: Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
Study: NCT02813083

Intervention type: OTHER
Intervention: No intervention (observational)
Description: No intervention (observational)
Study: NCT02515006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeopathy Medicine
Description: Homeopathy, or homeopathic medicine, is a holistic system of treatment. Individualized homeopathy remedy was based on the most characteristic and clear mental symptoms. Secondly, general symptoms were taken into account.C-potencies were provided and manufactured according to the Homeopathic Pharmacopoeia and Hahnemann's methodology. Each individualized homeopathic remedy were be prescribed in C-potencies
Study: NCT00004146

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxyamidotriazole
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02165410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASL-MRI
Description: ASL MRI is a non-invasive technique without injection to measure rCBF at rest marking the intravascular water molecules and use it as an endogenous tracer. Premedication, if required, will concern autistic and mentally retarded subjects only.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (diffusion MRI)
Description: Diffusion MRI enables the mapping of the diffusion process of water molecules, which allows visualizing anatomical connections between different parts of the brain, noninvasively and on an individual basis. The sequence is acquired following clinical MRI sequences, while the child is still inside the MRI machine, with no further intervention applied.
Study: NCT02324699

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab
Description: 300mg IV over 30 minutes. Both arms will receive vedolizumab at weeks 0, 2, and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: 300mg IV over 30 minutes. Both arms will receive vedolizumab at weeks 0, 2, and 6.
Study: NCT02165410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resting state MRI
Description: This sequence is based on the synchronization of fluctuations in the blood-oxygen level dependent (BOLD) signal of different brain regions that work as a network. Therefore this sequence allows for the establishing of maps of funcitonal connectivity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eye-tracking
Description: Eye tracking is a non-invasive method that allows objectifying gaze parameters during presentation of stimuli on a computer screen. Children will be presented with a series of social and no social stimuli and are required to watch it, with no further intervention applied.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive profile
Description: Children will be asked to perform certain tasks, adapted for their age.
Study: NCT03234361

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Phosphate Phase
Description: 2 capsules of sodium phosphate with 500mg/day of phosphate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low Phosphate Phase
Description: 2 capsules of sodium chloride.
Study: NCT03253120

Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: Patient/ Healthy volunteer will drink 5dl of Water

Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: Patient/ Healthy volunteer will drink 5dl of Water
Study: NCT00937092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: High-dose furosemide(HDF, furosemide 20 mg/h intravenously)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-dose dopamine + low-dose furosemide
Description: low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5μg/kg/min intravenously)
Study: NCT00628277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high caloric expenditure exercise
Description: high caloric expenditure exercise plus dietary counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low caloric expenditure exercise plus dietary counseling
Description: low caloric expenditure exercise plus dietary counseling
Study: NCT02684123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast
Description: Subjects will get drug or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03060382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balanced buttress absorbable spacer
Description: For the patients of study group, a balanced buttress absorbable spacer was placed into the gap after the osteotomy of tibia and fibula to modify the lower limb line.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: total knee arthroplasty
Description: Total knee arthroplasty was conducted for the patients of control group
Study: NCT04031196

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QLB
Description: QLB type 2 approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: classic TAP block approach
Study: NCT03257098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allo-APZ2-CVU
Description: Suspension of ABCB5-positive mesenchymal stem cells
Study: NCT02724566

Intervention type: DRUG
Group type: OTHER
Intervention: apelin
Description: Assessing the difference between the insulin sensitivity measured during hyperinsulinemic euglycemic clamps in the presence of a 2 hours continuous infusion of (PYR1)-apelin-13 (30nmol/kg) versus a 2 hours continuous infusion of placebo (vehicle alone).

Intervention type: DRUG
Group type: OTHER
Intervention: apelin
Description: Assessing the difference between the insulin sensitivity measured during hyperinsulinemic euglycemic clamps in the presence of a 2 hours continuous infusion of (PYR1)-apelin-13 (30nmol/kg) versus a 2 hours continuous infusion of placebo (vehicle alone).

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: 2 hours continuous infusion of placebo (vehicle alone) to compare with 2 hours infusion of apelin

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: 2 hours continuous infusion of placebo (vehicle alone) to compare with 2 hours infusion of apelin
Study: NCT03306979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N Acetylcysteine
Description: Patients will be randomized to receive N Acetylcysteine (NAC) (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening). The initial NAC dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Patients will receive four placebo capsules (lactose-based filler) given as 2 capsules in the morning and 2 capsules in the evening, which will be prepared to mimic the weight of the experimental capsules.The initial placebo dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
Study: NCT02121353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: Single-use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra-vitreal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF582
Description: Single-use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra-vitreal
Study: NCT00507065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed salts of a single-entity amphetamine (ADDERALL XR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed salts of a single-entity amphetamine (ADDERALL XR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed salts of a single-entity amphetamine (ADDERALL XR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed salts of a single-entity amphetamine (ADDERALL XR)
Study: NCT03362034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double transfer trays
Description: double trays one soft and one hard

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single transfer tray
Description: single soft tray
Study: NCT01052363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, CA4P

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, CA4P
Study: NCT00507065

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00638261

Intervention type: RADIATION
Group type: OTHER
Intervention: UVB-311nm
Description: UVB-311nm radiation given 3 times a week to one randomized body-half
Study: NCT03027245

Intervention type: DRUG
Intervention: Eribulin
Study: NCT03947593

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention is being administered.

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention is being administered.

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention is being administered.

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention is being administered.
Study: NCT04575584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Study: NCT04437446

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Case Group
Description: The additional examination corresponds to an OCTA which is a non-invasive examination, without potential risks, without radiation, using infrared light.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The additional examinations correspond to:~* OCTA which is a non-invasive examination, without potential risks, without radiation, using infrared light.~* OCT: non-invasive examination, without potential risks, without radiation, using infrared light. The patient must sit in front of a screen and a contact is taken without contact in about ten seconds.~* Visual field
Study: NCT03628716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301
Description: Prime with MVA-BN-CV301 (nominal titer 1.6 x 10\^9 Inf.U) given subcutaneously (SC) on Day 1 and Day 22. One dose = four 0.5 mL injections. One injection = nominal titer 4 x 10\^8 Inf.U in 0.5 mL.~Boost with FPV-CV301 (nominal titer of 1 × 10\^9 Inf.U in 0.5 mL, given SC every 21 days for 4 doses (on days 43, 64, 85, and 106), followed by boosts every 6 weeks until 6 months on trial (i.e., days 148 and 190), then every 12 weeks until completion of 2 years. One dose = one 0.5 mL injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab fixed dose of 1200 mg intravenous on Day 1 of each 21-day cycle
Study: NCT01215435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (under the skin) once daily, before breakfast. The trial has 3 treatment phases for both treatment arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (under the skin) once daily, before dinner. The trial has 3 treatment phases for both treatment arms
Study: NCT00511836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIVITROL 380 mg
Description: Administered via intramuscular (IM) injection once during the double-blind phase and for 2 additional injections, 4 weeks apart, during the optional open-label extension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching VIVITROL 380 mg was administered by IM injection once during the double-blind phase, only.
Study: NCT01943955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based computer gaming
Description: A computer mouse mounted to a headband and placed on the participant's head is used to interact with the game cursor. In order to interact with/play the game the participant must visually focus on the moving target and perform unpredictable head movements. Balance exercises are incorporated progressively and simultaneously during computer gaming.
Study: NCT01603199

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein high fiber diet
Description: A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein high fiber diet
Description: A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
Study: NCT01693770

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRgFUS
Description: Focused ultrasound energy is accumulated into the target tissue (skeletal metastasis) thanks to the real time guidance of the MR images.
Study: NCT00514982

Intervention type: DRUG
Group type: OTHER
Intervention: Mesalamine
Description: 5-Aminosalicylic Acid Derivative used to treat mild to moderate Ulcerative Colitis

Intervention type: DRUG
Group type: OTHER
Intervention: Infliximab
Description: Antirheumatic, Disease Modifying Gastrointestinal Agent, Miscellaneous, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat gastrointestinal disorders.

Intervention type: DRUG
Group type: OTHER
Intervention: Corticosteroids
Description: Systemic Corticosteroid used to treat inflammatory conditions.

Intervention type: DRUG
Group type: OTHER
Intervention: 6-Mercaptopurine
Description: Antineoplastic Agent, Antimetabolite, Immunosuppressant Agent used traditionally to treat Acute lymphoblastic leukemia. Unlabeled use as steroid-sparing agent for corticosteroid-dependent Crohn's disease (CD) and ulcerative colitis (UC); maintenance of remission in CD; fistulizing Crohn's disease.

Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Immunosuppressant Agent used to treat Liver, Heart, Kidney transplant, prevent host vs graft disease, severe atopic dermatitis.

Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab
Description: Antirheumatic, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat Rheumatoid arthritis and Crohn's disease.
Study: NCT00045734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00030823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QS21
Study: NCT00045734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00636480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Chlorhexidine gluconate (2% w/v) in an aqueous base, 26 ml applicator. Active drug contains alcohol and the placebo contains no drug. Administered topically.
Study: NCT01130324

Intervention type: DRUG
Intervention: VIBATIV
Description: Observational
Study: NCT00580749

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Naso jejunal feeding tube insertion
Description: Placement of feeding tube through nare and into jejunum for administration of enteral feeding.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NG feeding tube insertion
Description: Placement of naso gastric feeding tube into stomach for purpose of enteral feedings.
Study: NCT02133833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantum Spectrum Radiation Emitter
Description: The patients receive stimulation treatment of Quantum Spectrum Radiation Emitter (5 quantum chips) daily for three weeks. The emitters are placed around the shoulder.
Study: NCT02085070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: IV MK-3475

Intervention type: DRUG
Group type: OTHER
Intervention: MK-3475
Description: IV MK-3475
Study: NCT03331705

Intervention type: DEVICE
Intervention: Uro-C (Use of new cystoscope)
Description: Diagnostic cystoscopic procedure of the urethra and bladder
Study: NCT02157597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIRS based management
Description: 1. Check NIRS, mechanics, muscle relaxation, hemodynamics, ventilation, hematocrit, surgical repair~2. Deepen anesthesia with volatile or intravenous agent.~3. Consider Extra-Corporeal Membrane Oxygenation (ECMO).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: During the Control Arm, the medical team completes all tasks as clinically necessary and in the best medical interest of the patient, without any input from the study procedures
Study: NCT03063099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ReNu™ Injection
Description: Injection into the hip for the treatment of Osteoarthritis.
Study: NCT02481180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0001
Description: injection (SC) T0001 15mg weekly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0001
Description: injection (SC) T0001 30mg weekly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0001
Description: injection (SC) T0001 30mg every two weeks for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0001
Description: injection (SC) T0001 50mg every two weeks for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel
Description: injection (SC) enbrel 50mg twice a week for 12 weeks